依达拉奉联合尼莫地平在颅脑外伤治疗中的临床效果

董朝辉

（陕西省韩城市人民医院，陕西 渭南，715400）

浏览次数：59次 下载次数：324次

摘要：

目的 分析依达拉奉联合尼莫地平在颅脑外伤治疗中的临床效果。方法 选择本院在2013年3月至2016年3月收治的130例颅脑外伤患者，按治疗方法分成A组（71例）与B组（59例）。A组采用依达拉奉联合尼莫地平治疗，B组采用尼莫地平治疗。对比两组的昏迷情况、预后情况及临床疗效。结果 两组治疗前的GCS评分比较，差异无统计学意义（P>0.05）。治疗后，两组的GCS评分明显改善，且A组的GCS评分明显优于B组，差异有统计学意义（P<0.05）。治疗后3个月GOS评分显示，A组的恢复良好例数显著高于B组，且残疾、昏迷例数均低于B组，差异有统计学意义（P<0.05）。A组的治疗总有效率是 97.18%，高于B组的91.53%（P<0.05）。结论 采用依达拉奉联合尼莫地平治疗颅脑外伤具有较好的临床效果，可缩短患者的昏迷时间，具有显著的预后性，值得临床推广。

关键词：依达拉奉；尼莫地平；颅脑外伤

中图分类号：R651.1文献标志码：A文章编号：2096-1413(2017)16-0024-02

Clinical efficacy of edaravone and nimodipine in the treatment of patients with traumatic brain injury
DONG Zhao-hui
(People`s Hospital of Hancheng City, Weinan 715400, China)

ABSTRACT: Objective To analyze the clinical efficacy of edaravone and nimodipine on patients with traumatic brain injury. Methods A total of 130 cases of patients with traumatic brain injury admitted in our hospital from March 2013 to March 2016 were divided into group A (71 cases) and group B (59 cases) according to different treatment methods. The group A performed nimodipine and edaravone, while the group B was given nimodipine, and the coma, prognosis and clinical efficacy of the two groups were compared. Results There was no significant difference of GCS score between two groups before treatment (P>0.05); after treatment, the GCS scores of the two groups improved significantly, and the GCS score of group A was significantly better than that of group B (P<0.05). The GOS score of three months later showed that the number of good recovery cases in group A was significantly more than that in group B, and the number of disabled and coma were less than those of group B (P<0.05). The total effective rate of group A was 97.18%, which was significantly higher than 91.53% of group B (P<0.05). Conclusion Application of edaravone and nimodipine has better clinical efficacy in the treatment of patients with traumatic brain injury, with less coma duration, significant prognosis, which is worthy of clinical promotion.

KEYWORDS: edaravone; nimodipine; traumatic brain injury

参考文献：
[1] 邢鸣,魏民,张鹏,等.依达拉奉联合尼莫地平治疗颅脑外伤的效果观察[J].临床研究,2014,11(6):468-470.
[2] 向世清,陈建斌.依达拉奉联合尼莫地平治疗颅脑外伤用药效果初评[J].医学信息,2015,7(32):131-132.
[3] 仇振巍.尼莫地平联合依达拉奉治疗颅脑外伤术后并发脑梗死效果观察[J].河南外科学杂志,2015,21(6):56.
[4] 胡文,伍婷,邓国泉.368例颅脑外伤患者脑保护药物使用情况调查[J].中国药物滥用防治杂志,2011,17(1):40-42.
[5] 周峰,刘志祯,蔡华忠.颅脑外伤患者血糖与GCS评分及预后的相关性分析[J].中华全科医学,2013,11(5):682-683.
[6] 毛晓薇.天舒浸膏对急性脑缺血再灌注损伤的保护作用与机制研究[D].上海:第二军医大学,2012.
[7] 华杰,许园园.我院颅脑外伤脑保护药物使用情况调查[J].医药与保健,2014,22(2):73.
[8] 张盼盼,谭臻田.依达拉奉联合尼莫地平对颅脑外伤的治疗价值评析[J].国际医药卫生导报,2016,22(13):1961-1962.
[9] 封林森,马建华,印佳,等.早期高压氧联合依达拉奉对颅脑外伤患者血管活性因子的影响及疗效[J].中国血液流变学杂志,2013,9(4):685-687,694.
[10] 赵超,牟善玲,张玉海,等.依达拉奉对重度颅脑外伤患者预后及血浆8-表氧前列腺素F2α水平的影响[J].中国基层医药,2011,18(11):1468-1469.